Podcast
Questions and Answers
What is a key characteristic of L type voltage gated calcium channels?
What is a key characteristic of L type voltage gated calcium channels?
- They are activated by hyperpolarization
- They are permeable to sodium ions
- They are responsible for the upstroke of the action potential in cardiac myocytes (correct)
- They are primarily found in skeletal muscle
Which of the following is a physiology characteristic of calcium?
Which of the following is a physiology characteristic of calcium?
- It has no role in blood clotting
- It decreases the release of neurotransmitters at synapses
- It inhibits muscle contraction
- It acts as a secondary messenger in signal transduction pathways (correct)
How do DHP and Non-DHP calcium channel blockers (CCBs) differ?
How do DHP and Non-DHP calcium channel blockers (CCBs) differ?
- DHP CCBs primarily target cardiac calcium channels
- DHP CCBs have a stronger effect on smooth muscle cells
- Non-DHP CCBs are more effective in reducing peripheral vascular resistance (correct)
- Non-DHP CCBs are contraindicated in hypertension
In the context of calcium channel blockers (CCBs), which factor is included in the pharmacokinetic profile?
In the context of calcium channel blockers (CCBs), which factor is included in the pharmacokinetic profile?
What condition should be considered when deciding to use or avoid calcium channel blockers (CCBs)?
What condition should be considered when deciding to use or avoid calcium channel blockers (CCBs)?
What is a key characteristic of L type voltage gated calcium channels?
What is a key characteristic of L type voltage gated calcium channels?
Which factor is NOT typically a pharmacokinetic profile detail of calcium channel blockers (CCBs)?
Which factor is NOT typically a pharmacokinetic profile detail of calcium channel blockers (CCBs)?
What is a common adverse drug reaction (ADR) associated with calcium channel blockers (CCBs)?
What is a common adverse drug reaction (ADR) associated with calcium channel blockers (CCBs)?
Which of the following conditions is important to consider when deciding to use or avoid calcium channel blockers (CCBs)?
Which of the following conditions is important to consider when deciding to use or avoid calcium channel blockers (CCBs)?
What effect do calcium channel blockers (CCBs) have on coronary blood flow?
What effect do calcium channel blockers (CCBs) have on coronary blood flow?
What is a key characteristic of L type voltage gated calcium channels?
What is a key characteristic of L type voltage gated calcium channels?
Which factor is NOT typically a pharmacokinetic profile detail of calcium channel blockers (CCBs)?
Which factor is NOT typically a pharmacokinetic profile detail of calcium channel blockers (CCBs)?
How do dihydropyridine (DHP) and non-dihydropyridine (Non-DHP) calcium channel blockers (CCBs) differ?
How do dihydropyridine (DHP) and non-dihydropyridine (Non-DHP) calcium channel blockers (CCBs) differ?
What condition should be considered when deciding to use or avoid calcium channel blockers (CCBs)?
What condition should be considered when deciding to use or avoid calcium channel blockers (CCBs)?
What effect do calcium channel blockers (CCBs) have on plasma renin?
What effect do calcium channel blockers (CCBs) have on plasma renin?
What is a distinguishing feature of L type voltage-gated calcium channels?
What is a distinguishing feature of L type voltage-gated calcium channels?
Which condition should generally be avoided when considering the use of calcium channel blockers (CCBs)?
Which condition should generally be avoided when considering the use of calcium channel blockers (CCBs)?
What effect do calcium channel blockers (CCBs) typically have on cardiac contractility?
What effect do calcium channel blockers (CCBs) typically have on cardiac contractility?
In terms of pharmacokinetics, which detail is often associated with dihydropyridine (DHP) calcium channel blockers?
In terms of pharmacokinetics, which detail is often associated with dihydropyridine (DHP) calcium channel blockers?
What is a possible effect of calcium channel blockers (CCBs) on left ventricular hypertrophy?
What is a possible effect of calcium channel blockers (CCBs) on left ventricular hypertrophy?